Skip to content
HowShorted

Esperion Therapeutics, Inc. short interest in 2021

In 2021, Esperion Therapeutics, Inc.'s disclosed short interest ran from 39.75% of shares outstanding on 15 Jan 2021 to 29.76% on 31 Dec 2021, a change of -9.99 percentage points. The year's high was 39.75% on 15 Jan 2021 and its low 25.90% on 30 Sep 2021, averaging 32.27% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.54 days on 30 Apr 2021. Full history: Esperion Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Esperion Therapeutics, Inc. in 2021

2021 in figures

Start of year
39.75% (15 Jan 2021)
End of year
29.76% (31 Dec 2021)
Change
-9.99 pp
High
39.75% (15 Jan 2021)
Low
25.90% (30 Sep 2021)
Average
32.27%
Highest days to cover
26.54 (30 Apr 2021)
SEC filings marked
10

Every report in 2021

Esperion Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202139.75%13.73results (8-K)
29 Jan 202136.37%7.27
12 Feb 202134.16%13.15
26 Feb 202136.17%15.7510-K filed, results (8-K)
15 Mar 202134.94%17.90
31 Mar 202133.87%18.61
15 Apr 202134.96%24.13
30 Apr 202134.67%26.54
14 May 202132.40%7.0810-Q filed, results (8-K)
28 May 202131.88%12.74
15 Jun 202131.74%16.71
30 Jun 202132.04%21.45
15 Jul 202133.69%15.38
30 Jul 202131.99%14.10
13 Aug 202130.85%12.0710-Q filed, results (8-K)
31 Aug 202128.63%15.94
15 Sep 202128.80%8.64
30 Sep 202125.90%7.73
15 Oct 202128.19%8.50
29 Oct 202132.47%6.80results (8-K)
15 Nov 202130.48%6.7610-Q filed, results (8-K)
30 Nov 202133.97%4.55
15 Dec 202126.88%1.43
31 Dec 202129.76%5.52

See also: Esperion Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.